Chimerix (CMRX) has named its chief medical officer, Michelle Berrey, as CEO to replace Kenneth Moch, who has resigned to "pursue other interests."
Berrey will continue to serve as Chimerix's CMO.
In March, Chimerix caused a storm by initially refusing to supply its Brincidofovir (CMX001) treatment to a seven-year-old boy who was dying from an adenovirus infection.
The company explained that Brincidofovir wasn't authorized, but it eventually caved and provided the drug. (PR)